Micafungin (Mycamine®) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (MICADO).

Trial Profile

Micafungin (Mycamine®) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (MICADO).

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Micafungin (Primary)
  • Indications Aspergillosis; Candidaemia; Candidiasis
  • Focus Pharmacokinetics
  • Acronyms MICADO
  • Most Recent Events

    • 24 Apr 2018 Results assessing pharmacokinetics of micafungin in obese and normal-weight subjects were presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
    • 26 Sep 2017 Status changed from recruiting to completed.
    • 07 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top